Mainboard · BSE and NSEDraft filed

Virupaksha Organics Limited IPO: dates, price band, lot size, objects of the issue

Get updates on this IPO

Dates, price band, allotment and listing notices by email, and new views from SEBI-registered research analysts on InsightPier by email.

Dates, allotment, listing and analyst views. Stop anytime.

By continuing you agree to the Terms and Privacy policy

Updated Sun 8 Nov 2026, 8:20 pm IST · Source: DRHP dated Mon 29 Sep 2025

Key facts

Price band
Not announced
Lot size
Not announced
Lot amount at the upper band
Not announced
Issue size at the upper band
₹740.00 crore
Fresh issue
₹740.00 crore
DRHP dated Mon 29 Sep 2025, page 1
Offer for sale
None
DRHP dated Mon 29 Sep 2025, page 1
Bid dates
Not announced
Listing date
Not announced
Risk factors
79
DRHP dated Mon 29 Sep 2025, page 73
Proposed exchanges
BSE and NSE

Timeline (IST)

  1. Draft filedWed 8 Oct 2025 confirmedDRHP dated Mon 29 Sep 2025
  2. OpensDates to be announced
  3. ClosesDates to be announced
  4. AllotmentDates to be announced
  5. Refund and unblockDates to be announced
  6. ListingDates to be announced

Objects of the issue

ObjectAmount
Funding capital expenditure requirement for capacity expansion at the Expansion Units₹360.00 crore
Prepayment of all or a portion of certain outstanding borrowings availed by our Company₹195.00 crore
General corporate purposesNot stated in the draft
TotalNot stated in the draft

DRHP dated Mon 29 Sep 2025, page 122

Company and promoters

As described in the DRHP

We are a research and development (“R&D”) driven Indian pharmaceutical company engaged in the manufacture of active pharmaceutical ingredients (“APIs”) and intermediates.

DRHP dated Mon 29 Sep 2025, page 27

Promoters

  • 9 individual promoters

DRHP dated Mon 29 Sep 2025, page 27

Shareholding

HoldingBefore the issueAfter the issue
Promoters and promoter group59.84%Not stated in the DRHP
Public40.16%Not stated in the DRHP

DRHP dated Mon 29 Sep 2025, page 116

Financials (restated)

ItemMarch 31, 2025March 31, 2024March 31, 2023
Revenue from operations₹811.71 crore₹765.99 crore₹644.84 crore
Profit after tax₹78.71 crore₹73.68 crore₹43.09 crore
Net worth₹456.62 crore₹275.31 crore₹209.71 crore
Total borrowings₹282.23 crore₹264.35 crore₹240.85 crore

DRHP dated Mon 29 Sep 2025, page 78

Peer comparison (as in the DRHP)

Name of the CompanyStandalone / ConsolidatedTotal Revenue (₹ in million)Face Value per Equity Share (₹)Closing price as on September 26, 2025P/EEPS (Basic and Diluted) (₹) BasicEPS (Basic and Diluted) (₹) DilutedRoNW (%)NAV (₹ per share)
Our CompanyConsolidated8,117.0910.00NA[●]*13.1713.1717.25111.25
Supriya Lifescience LimitedStandalone6,964.852.00700.9530.0223.3523.3519.17121.85
Alivus Life Sciences LimitedStandalone23,868.842.00933.4523.6239.6339.5217.24229.92
Divi's Laboratories LimitedConsolidated93,600.002.005690.3068.9582.5382.5314.67562.70
Laurus Labs LimitedConsolidated55,539.602.00832.70125.416.656.648.1981.13
Aarti Drugs LimitedConsolidated23,870.3010.00470.0025.6118.3518.3512.33149.32
Neuland Laboratories LimitedConsolidated14,768.3710.0013,954.4568.83202.74202.7417.081,186.90

Reproduced from the DRHP dated Mon 29 Sep 2025, page 147; InsightPier adds no figures

Risk factors

79 total
  1. Most revenue comes from analgesic, anti-histamine and anti-fungal products; lower demand for them could hurt the business (DRHP page 37)
  2. Manufacturing units face regulator and customer inspections; quality problems could bring regulatory action (DRHP page 38)
  3. A large share of revenue comes from a few key customers; losing them could hurt results (DRHP page 39)
  4. Karnataka pollution board notices and closure directions for Unit 3 and Unit 6; shutdowns could hurt operations (DRHP page 39)
  5. Hazardous operations and materials could cause accidents, suspensions and liabilities (DRHP page 41)

All 79 risk factors, DRHP pages 37 to 73

Offer document

Research

Research reports on IPOs from SEBI-registered research analysts, published on InsightPier.

Research reports on IPOs from SEBI-registered research analysts